Do analysts prefer NAGE or BWMX?

Niagen Bioscience presently has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Betterware de Mexico SAPI de C 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media favor NAGE or BWMX?

In the previous week, Niagen Bioscience had 2 more articles in the media than Betterware de Mexico SAPI de C. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Betterware de Mexico SAPI de C. Betterware de Mexico SAPI de C's average media sentiment score of 1.16 beat Niagen Bioscience's score of 0.28 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Betterware de Mexico SAPI de C 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HNST or NAGE?

In the previous week, Niagen Bioscience had 3 more articles in the media than Honest. MarketBeat recorded 6 mentions for Niagen Bioscience and 3 mentions for Honest. Honest's average media sentiment score of 1.48 beat Niagen Bioscience's score of 0.28 indicating that Honest is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Honest 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRE or NAGE?

In the previous week, Niagen Bioscience had 2 more articles in the media than Prenetics Global. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.60 beat Niagen Bioscience's score of 0.28 indicating that Prenetics Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate USNA or NAGE?

Niagen Bioscience has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than USANA Health Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score USANA Health Sciences 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media refer more to USNA or NAGE?

In the previous week, Niagen Bioscience had 5 more articles in the media than USANA Health Sciences. MarketBeat recorded 6 mentions for Niagen Bioscience and 1 mentions for USANA Health Sciences. Niagen Bioscience's average media sentiment score of 0.28 beat USANA Health Sciences' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment USANA Health Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NAGE or YSG?

Niagen Bioscience presently has a consensus price target of $10.33, indicating a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Niagen Bioscience is more favorable than Yatsen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Yatsen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Niagen Bioscience (NAGE) Competitors

$3.04 +0.04 (+1.16%)

As of 02:23 PM Eastern

Compare

NAGE vs. BWMX, HNST, PRE, USNA, and YSG

Should you buy Niagen Bioscience stock or one of its competitors? Niagen Bioscience's main competitors and comparable companies include Betterware de Mexico SAPI de C (BWMX), Honest (HNST), Prenetics Global (PRE), USANA Health Sciences (USNA), and Yatsen (YSG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Niagen Bioscience presently has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Betterware de Mexico SAPI de C	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.67

Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, Betterware de Mexico SAPI de C has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to Betterware de Mexico SAPI de C's net margin of 8.35%. Betterware de Mexico SAPI de C's return on equity of 77.89% beat Niagen Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Betterware de Mexico SAPI de C	8.35%	77.89%	11.28%

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.92
Betterware de Mexico SAPI de C	$14.85B	0.04	$55.37M	$1.83	9.16

In the previous week, Niagen Bioscience had 2 more articles in the media than Betterware de Mexico SAPI de C. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Betterware de Mexico SAPI de C. Betterware de Mexico SAPI de C's average media sentiment score of 1.16 beat Niagen Bioscience's score of 0.28 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Betterware de Mexico SAPI de C	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 12.7% of Betterware de Mexico SAPI de C shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 11 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Honest?

Honest (NASDAQ:HNST) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

Niagen Bioscience has a net margin of 12.39% compared to Honest's net margin of -3.56%. Niagen Bioscience's return on equity of 17.95% beat Honest's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Honest	-3.56%	4.31%	3.33%
Niagen Bioscience	12.39%	17.95%	13.17%

In the previous week, Niagen Bioscience had 3 more articles in the media than Honest. MarketBeat recorded 6 mentions for Niagen Bioscience and 3 mentions for Honest. Honest's average media sentiment score of 1.48 beat Niagen Bioscience's score of 0.28 indicating that Honest is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Honest	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has lower revenue, but higher earnings than Honest. Honest is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Honest	$371.32M	1.56	-$15.69M	-$0.11	N/A
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.92

45.5% of Honest shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 9.4% of Honest shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Honest has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Honest currently has a consensus target price of $4.84, indicating a potential downside of 8.25%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Honest.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Honest	2 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.22
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Niagen Bioscience beats Honest on 12 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Prenetics Global presently has a consensus target price of $35.67, suggesting a potential upside of 53.84%. Niagen Bioscience has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 7.8% of Prenetics Global shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Niagen Bioscience has a net margin of 12.39% compared to Prenetics Global's net margin of -47.43%. Niagen Bioscience's return on equity of 17.95% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-47.43%	-21.41%	-15.56%
Niagen Bioscience	12.39%	17.95%	13.17%

In the previous week, Niagen Bioscience had 2 more articles in the media than Prenetics Global. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.60 beat Niagen Bioscience's score of 0.28 indicating that Prenetics Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prenetics Global has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

Niagen Bioscience has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	4.23	-$37.71M	-$4.16	N/A
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.92

Summary

Niagen Bioscience beats Prenetics Global on 13 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to USANA Health Sciences?

USANA Health Sciences (NYSE:USNA) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

54.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 0.8% of USANA Health Sciences shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Niagen Bioscience had 5 more articles in the media than USANA Health Sciences. MarketBeat recorded 6 mentions for Niagen Bioscience and 1 mentions for USANA Health Sciences. Niagen Bioscience's average media sentiment score of 0.28 beat USANA Health Sciences' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
USANA Health Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

USANA Health Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to USANA Health Sciences' net margin of -2.43%. Niagen Bioscience's return on equity of 17.95% beat USANA Health Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	-2.43%	3.41%	2.50%
Niagen Bioscience	12.39%	17.95%	13.17%

Niagen Bioscience has lower revenue, but higher earnings than USANA Health Sciences. USANA Health Sciences is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$925.26M	0.29	$10.76M	-$1.21	N/A
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.92

Niagen Bioscience has a consensus target price of $10.33, suggesting a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Niagen Bioscience beats USANA Health Sciences on 15 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Yatsen?

Niagen Bioscience (NASDAQ:NAGE) and Yatsen (NYSE:YSG) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Niagen Bioscience presently has a consensus price target of $10.33, indicating a potential upside of 239.35%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Niagen Bioscience is more favorable than Yatsen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Yatsen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Yatsen has a beta of -1.54, suggesting that its share price is 254% less volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to Yatsen's net margin of -4.63%. Niagen Bioscience's return on equity of 17.95% beat Yatsen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Yatsen	-4.63%	-7.26%	-5.42%

15.4% of Niagen Bioscience shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 29.0% of Yatsen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience has higher earnings, but lower revenue than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.92
Yatsen	$614.62M	0.39	-$11.56M	-$0.32	N/A

In the previous week, Niagen Bioscience had 6 more articles in the media than Yatsen. MarketBeat recorded 6 mentions for Niagen Bioscience and 0 mentions for Yatsen. Niagen Bioscience's average media sentiment score of 0.28 beat Yatsen's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Neutral
Yatsen	Neutral

Summary

Niagen Bioscience beats Yatsen on 15 of the 17 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$242.50M	$22.95B	$15.55B	$13.16B
Dividend Yield	N/A	5.09%	3.27%	12.57%
P/E Ratio	16.92	21.05	14.14	25.81
Price / Sales	1.87	12.77	262,948.98	110.54
Price / Cash	15.24	27.44	56.96	52.76
Price / Book	3.17	2.88	4.32	6.32
Net Income	$17.38M	$1.13B	$837.18M	$359.77M
7 Day Performance	1.84%	-0.49%	-0.81%	-0.15%
1 Month Performance	-6.88%	-5.98%	-4.42%	-4.08%
1 Year Performance	-67.64%	-13.89%	10.14%	6.16%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	3.2963 of 5 stars	$3.05 +1.2%	$10.33 +239.4%	-68.4%	$242.50M	$129.42M	16.92	117	News Coverage
BWMX Betterware de Mexico SAPI de C	4.6805 of 5 stars	$16.06 -0.4%	N/A	+24.9%	$634.21M	$744M	8.78	2,441	Positive News Analyst Upgrade
HNST Honest	2.5087 of 5 stars	$5.36 +0.3%	$4.84 -9.6%	+37.5%	$588.38M	$371.32M	N/A	174	Positive News Analyst Upgrade
PRE Prenetics Global	4.3236 of 5 stars	$24.83 +12.8%	$35.67 +43.6%	+67.4%	$418.88M	$92.39M	N/A	98	News Coverage
USNA USANA Health Sciences	1.1385 of 5 stars	$14.44 -1.9%	N/A	-50.7%	$266.94M	$925.26M	N/A	1,570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. BWMX, HNST, PRE, USNA, and YSG

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Summary

How does Niagen Bioscience compare to Honest?

Summary

How does Niagen Bioscience compare to Prenetics Global?

Summary

How does Niagen Bioscience compare to USANA Health Sciences?

Summary

How does Niagen Bioscience compare to Yatsen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. BWMX, HNST, PRE, USNA, and YSG

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Do analysts prefer NAGE or BWMX?

Which has more volatility & risk, NAGE or BWMX?

Is NAGE or BWMX more profitable?

Which has better earnings & valuation, NAGE or BWMX?

Does the media favor NAGE or BWMX?

Do insiders & institutionals believe in NAGE or BWMX?

Summary

How does Niagen Bioscience compare to Honest?

Is HNST or NAGE more profitable?

Does the media refer more to HNST or NAGE?

Which has stronger valuation and earnings, HNST or NAGE?

Do institutionals and insiders have more ownership in HNST or NAGE?

Which has more volatility & risk, HNST or NAGE?

Do analysts rate HNST or NAGE?

Summary

How does Niagen Bioscience compare to Prenetics Global?

Do analysts prefer PRE or NAGE?

Do insiders & institutionals have more ownership in PRE or NAGE?

Is PRE or NAGE more profitable?

Does the media prefer PRE or NAGE?

Which has more risk and volatility, PRE or NAGE?

Which has preferable earnings & valuation, PRE or NAGE?

Summary

How does Niagen Bioscience compare to USANA Health Sciences?

Do institutionals and insiders have more ownership in USNA or NAGE?

Does the media refer more to USNA or NAGE?

Which has more risk and volatility, USNA or NAGE?

Is USNA or NAGE more profitable?

Which has better earnings & valuation, USNA or NAGE?

Do analysts rate USNA or NAGE?

Summary

How does Niagen Bioscience compare to Yatsen?

Do analysts rate NAGE or YSG?

Which has more risk & volatility, NAGE or YSG?

Is NAGE or YSG more profitable?

Do institutionals & insiders believe in NAGE or YSG?

Which has preferable earnings & valuation, NAGE or YSG?

Does the media refer more to NAGE or YSG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools